HebaBiz Biotech Obtains FDA Clearance to Trial Cancer Drug Against Aggressive Brain Tumor

2021-08-22| China

HebaBiz Biotech Obtains FDA Clearance to Trial Cancer Drug Against Aggressive Brain Tumor

by Rajaneesh K. Gopinath

Share To

Glioblastoma (GBM) is the most common and aggressive form of brain tumor with a poor prognosis. Existing treatment includes surgery, followed by radiotherapy, and chemotherapy. Yet, several patients develop resistance to treatments, suffer from relapse, and die, creating a significant unmet need in this area.

At this juncture, Beijing-based HebaBiz Biotech announces that the FDA has accepted IND for its innovative anti-cancer drug for Glioblastoma trials in the US.

GO Prime with only $1.49 now

SUBSCRIBE NOW

LATEST

Six Game-Changing Cancer Treatments Built for Unstoppable Growth in 2025 – Part II

2024-12-11

Six Game-Changing Cancer Treatments Built for Unstoppable Growth in 2025 – Part I

2024-12-11

Healthcare Revolution: Leeuwenhoek Joins Hands with Key Companies and Experts at Healthcare+ Expo Taiwan 2024

2024-12-11

2024 Taiwan Healthcare+ Expo: Innovations in Five Key Industries

2024-12-11

Core8 Group and MedArmor to Pioneer Vietnam’s First AI x ESG Hospital

2024-12-10

The Future of Generative AI for New Drug Development and Precision Medicine

2024-12-09

How FIRM is Shaping Regenerative Medicine in Japan

2024-12-09

EVENT

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

GENE ONLINE|News &
Opinion
Blog